Psychiatric Quarterly

, Volume 71, Issue 4, pp 309–329 | Cite as

Functional Impairment and Cognition in Bipolar Disorder

  • Carlos A. ZarateJr.
  • Mauricio Tohen
  • Michelle Land
  • Sarah Cavanagh


Bipolar disorder is a common, chronic and severe mental disorder, affecting approximately 2% of the adult population. Bipolar disorder causes substantial psychosocial morbidity that frequently affects the patient's marriage, children, occupation, and other aspects of the patient's life. Few studies have examined the functional impairment in patients with affective illness. Earlier outcome studies of mania reported favorable long-term outcomes. However, modern outcome studies have found that a majority of bipolar patients evidence high rates of functional impairment. These low reports of functional recovery rates are particularly surprising. The basis for such limited functional recovery is not entirely clear. Factors associated with functional dysfunction include presence of inter-episode symptoms, neuroleptic treatment, lower social economic class, and lower premorbid function. Cognitive dysfunction, a symptom domain of schizophrenia, has been identified as an important measure of outcome in the treatment of schizophrenia. Recently, there has been some suggestion that there may be impaired neuropsychological performance in euthymic patients with recurring mood disorders. Whether impaired neuropsychological performance in associated with the functional impairment in bipolar patients who have achieved syndromal recovery is an intriguing question. The literature on functional impairment and cognition in bipolar disorder is reviewed.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Angst J: Switch from depression to mania-a record study over decades between 1920 and 1982. Psychopathology 18(2-3):140–54, 1985.Google Scholar
  2. Atre-Vaidya N, Taylor MA, Seidenberg M, Reed R, Perrine A, Glick-Oberwise F, Cognitive deficits, psychopathology, and psychosocial functioning in bipolar mood disorder. Neuropsychiatry, Neuropsychology, &; Behavioral Neurology 11(3):120–6, 1998.Google Scholar
  3. Bellini L, Gambini O, Palladino F, Scarone S: Neuropsychological assessment of functional central nervous system disorders. I. Hemispheric functioning characteristics in schizophrenia and affective illness. Acta Psychiatrica Scandinavica 78(2):242–6, 1988 Aug.Google Scholar
  4. Bratfos O, Haug JO: The course of manic-depressive psychosis: a follow-up investigation of 215 patients. Acta Psychiatr Scand 44:89–112, 1968.Google Scholar
  5. Cannon M, Jones P, Gilvarry C, Rifkin L, McKenzie K, Foerster A, Murray RM: Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences. Am J Psychiatry 154:1544–1550, 1997.Google Scholar
  6. Carlson GA, Kotin J, Davenport YM, et al.: Follow-up of 53 bipolar manic-depressive patients. Br J Psychiatry 124:134–139, 1974.Google Scholar
  7. Coffman JA, Bornstein RA, Olson SC, Schwarzkopf SB, Nasrallah HA: Cognitive impairment and cerebral structure by MRI in bipolar disorder. Biol Psychiatry 1;27 (11):1188–96, 1990 Jun.Google Scholar
  8. Cooke RG, Robb JC, Young LT, Joffee RT: Well-being and functioning in patients with bipolar disorder assessed using the MOS 20-item short form (SF-20). J Affect Disord 39:93–97, 1996.Google Scholar
  9. Coryell W, Scheftner W, Keller M, et al.: The enduring psychosocial consequences of mania and depression. Am J Psychiatry 150:720–727, 1993.Google Scholar
  10. Dion GL, Tohen M, Anthony WA, et al.: Symptoms and functioning of patients with bipolar disorder six months after hospitalization. Hosp Community Psychiatry 39:652–657, 1988.Google Scholar
  11. Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H: Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 6(Suppl 2):S13–S20, 1996.Google Scholar
  12. Ghaemi SN, Sachs GS: Long-term risperidone treatment in bipolar disorder: 6-month follow up. International Clinical Psychopharmacology 12(6):333–8, 1997 Nov.Google Scholar
  13. Gitlin MJ, Swendson J, Heller TL, et al.: Relapse and impairment in bipolar disorder. Am J Psychiatry 152:1635–1640, 1995.Google Scholar
  14. Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L: A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry 60:733–740, 1999Google Scholar
  15. Goldberg JF, Harrow M, Grossman LS: Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry 152:379–384, 1995.Google Scholar
  16. Goldberg JF, Harrow M, eds.: Bipolar Disorders. Clinical Course and Outcome. American Psychiatric Press, Inc. 1999, pg. 5Google Scholar
  17. Goodnick PJ, Fieve RR: Plasma lithium level and interepisode functioning in bipolar disorder. American Journal of Psychiatry 142(6):761–2, 1985 Jun.Google Scholar
  18. Goodwin FK, Jamison KR: Manic-Depressive Illness. New York: Oxford University Press. 1990.Google Scholar
  19. Harrow M, Goldberg JF, Grossman LS, et al.: Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 47:665–671, 1990.Google Scholar
  20. Harvey PD, Powchick P, Parrella M, White L, Davidson M: Symptom severity and cognitive impairment in chronically hospitalized. geriatric patients with affective disorders. British Journal of Psychiatry 170:369–74, 1997 Apr.Google Scholar
  21. Hawkins KA, Mohamed S, Woods SW: Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia? Psychol Med 29(1):1–8, 1999 Jan.Google Scholar
  22. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux CM, Oepen G: One hundred years of schizophrenia: A meta-analysis of the outcome literature. Am J Psychiatry 151:1409–1416, 1994.Google Scholar
  23. Henry AD, Coster WJ: Predictors of functional outcome among adolescents and young adults with psychotic disorders. American Journal of Occupational Therapy 50(3):171–81, 1996 Mar.Google Scholar
  24. Himmelhoch JM, Garfinkel ME: Sources of lithium resistance in mixed mania. Psychopharmacol Bull 22:613–620, 1986.Google Scholar
  25. Joffe RT: MacDonald C: Kutcher SP: Lack of differential cognitive effects of lithium and carbamazepine in bipolar affective disorder. Journal of Clinical Psychopharmacology 8(6):425–8, 1988 Dec.Google Scholar
  26. Keck PE Jr, McElroy SL, Strakowski SM, West SA, Sax KW, Hawkins JM, Bourne ML, Haggard P: 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 155:646–652, 1998.Google Scholar
  27. Keller MB, Lavori PW, Coryell W, Andreasen NC, Endicott J, Clayton PJ, Klerman GL, Hirschfeld RM: Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. Journal of the American Medical Association 255:3138–3142, 1986.Google Scholar
  28. Kraepelin E: Manic-Depressive Insanity (1921). Translated by Barclay RM. Edinburgh, Scotland, Linvingstone. Reprint, New York, Arno Press, 1976.Google Scholar
  29. Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L: Course of the manic-depressive cycle and changes caused by treatments. Pharmakopsychiatr Neuropsychopharmakol 13:156–167, 1980.Google Scholar
  30. Laroche I, Hodgins S, Toupin J: [Correlation between symptoms and social adjustment in patients suffering from schizophrenia or major affective disorder]. [French] Canadian Journal of Psychiatry-Revue Canadienne de Psychiatrie 40(1):27–34, 1995 Feb.Google Scholar
  31. MacQueen GM, Young LT, Robb JC, Cooke RG, Joffe RT. Levels of functioning and well-being in recovered psychotic versus nonpsychotic mania. J Affect Disord 46:69–72 1997.Google Scholar
  32. Mayfield D, Coleman LL: Alcohol use and affective disorder. Dis Nerv Syst 29:467–474, 1968.Google Scholar
  33. Meltzer HY, Thompson PA, Lee MA, Ranjan R: Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology 14:27S–33S, 1996.Google Scholar
  34. Meltzer HY, McGurk SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233–55, 1999.Google Scholar
  35. Morrison JR: Bipolar affective disorder and alcoholism. Am J Psychiatry 131:1130–1133, 1974.Google Scholar
  36. O'Connell RA, Mayo JA, Flatow L, et al.: Outcome of bipolar disorder on longterm treatment with lithium. Br J psychiatry 159:123–129, 1991.Google Scholar
  37. Paradiso S, Lamberty GJ, Garvey MJ, Robinson RG: Cognitive impairment in the euthymic phase of chronic unipolar depression. Journal of Nervous &; Mental Disease 185(12):748–54, 1997 Dec.Google Scholar
  38. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 57(3):249-58 200 Mar.Google Scholar
  39. Rennie TAC. Prognosis in manic-depressive psychoses. Am J Psychiatry 98:801–814, 1942.Google Scholar
  40. Robb JC, Young LT, Cooke RG, Joffe RT: Gender differences in patients with bipolar disorder influence outcome in the medical outcomes survey (SF-20) subscale scores. Journal of Affective Disorders. 49(3):189–93, 1998.Google Scholar
  41. Rosen LN, Rosenthal NE, Dunner DL, Fieve RR: Social outcome compared in psychotic and nonpsychotic bipolar I patients. J Nerv Ment Dis 171(5):272–5, 1983 May.Google Scholar
  42. Savard RJ, Rey AC, Post RM: Halstead-Reitan Category Test in bipolar and unipolar affective disorders. Relationship to age and phase of illness. Journal of Nervous &; Mental Disease 168(5):297–304, 1980.Google Scholar
  43. Sax KW, Strakowski SM, Keck PE Jr, McElroy SL, West SA, Stanton SP: Symptom correlates of attentional improvement following hospitalization for a first episode of affective psychosis. Biol Psychiatry 44(8):784–786, 1998.Google Scholar
  44. Segal J, Berk M, Brook S: Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clinical Neuropharmacology 21:176–180, 1998.Google Scholar
  45. Sharma T, Mockler D: The cognitive efficacy of atypical antipsychotics in schizophrenia. J Clin Psychopharmacol 18:12S–19S1, 1998.Google Scholar
  46. Solomon DA, Ristow WR, Keller MB, Kane JM, Gelenberg AJ, Rosenbaum JF: Serum lithium levels and psychosocial function in patients with bipolar disorder. American Journal of Psychiatry 153(10):1301–7, 1996 Oct.Google Scholar
  47. Sonne SC, Brady KT, Morton WA: Substance abuse and bipolar affective disorder. J Nerv Ment Dis 182:349–352, 1994.Google Scholar
  48. Strakowski SM, Keck PE Jr, McElroy SL, et al. Twelve-month outcome after a first hospitalization for affective psychosis. Arch Gen Psychiatry 55:49–55, 1988.Google Scholar
  49. Tham A, Engelbrektson K, Mathe AA, Johnson L, Olsson E, Aberg-Wistedt A: Impaired neuropsychological performance in euthymic patients with recurring mood disorders. Journal of Clinical Psychiatry 58:26–29, 1997.Google Scholar
  50. Tohen M, Hennen J, Zarate CA Jr, Baldessarini RJ, Strakowski SM, Stoll AL, Faedda GL, Suppes T, Gebre-Medhin P, Cohen BM: The McLean First Episode Project: Two-year syndromal and functional recovery in 219 cases of major affective disorders with psychotic features. Am J Psychiatry 157:220–228, 2000.Google Scholar
  51. Tohen M, Greenfield SF, Weiss RD, Zarate CA Jr, Vagge LM: The effect of comorbid substance use disorders on the course of bipolar disorder: A review. Harvard Rev Psychiatry 6:133–141, 1998a.Google Scholar
  52. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa R, Daniel D, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V and the olanzapine HGEH study group. Am J Psychiatry 156:702–709, 1999.Google Scholar
  53. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 47:1106–1111, 1990.Google Scholar
  54. Tohen M, Zarate CA Jr, Centorrino F, Hegarty J, Froeschl M, Zarate SB: Risperidone in the treatment of mania. J Clin Psychiatry 57:249–253, 1996.Google Scholar
  55. Tohen M, Zarate CA Jr: Antipsychotic Drugs in Bipolar Disorder. J Clin Psychiatry 59[suppl 1]:38–48, 1998b.Google Scholar
  56. Tsuang MT, Woolson RF, Fleming JA: Long-term outcome of major psychoses; I: schizophrenia and affective disorders compared with psychiatrically symptom-free surgical controls. Arch Gen Psychiatry 39:1295–1301, 1979.Google Scholar
  57. van Gorp WG, Altshuler L, Theberge DC, Wilkins J, Dixon W: Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. A preliminary study. Arch Gen Psychiatry 55:41–6, 1998.Google Scholar
  58. Zarate CA Jr, Narendran R, Tohen M, Greaney JJ, Berman A, Pike S, Madrid A. Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry 59:24–28, 1998.Google Scholar
  59. Zarate CA Jr, Tohen M, Baldessarini RJ: Clozapine in severe mood disorders. J Clin Psychiatry 56:411–417, 1995.Google Scholar
  60. Zarate CA Jr, Tohen M: Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study. J Clin Psychiatry 61:33–38, 2000.Google Scholar

Copyright information

© Human Sciences Press, Inc. 2000

Authors and Affiliations

  • Carlos A. ZarateJr.
    • 1
  • Mauricio Tohen
    • 2
    • 3
  • Michelle Land
    • 4
  • Sarah Cavanagh
    • 4
  1. 1.The Bipolar and Psychotic Disorders ProgramUniversity of Massachusetts Medical SchoolWorcester
  2. 2.Harvard Medical SchoolMcLean HospitalBelmont
  3. 3.Lilly Research LaboratoriesIndianapolis
  4. 4.The Bipolar and Psychotic Disorders ProgramUniversity of Massachusetts Medical SchoolWorcester

Personalised recommendations